Trial Profile
An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Asperger syndrome; Autistic disorder; Pervasive child development disorders
- Focus Adverse reactions
- Sponsors Forest Laboratories
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 10 Jul 2019 As per European Clinical Trials Database record this trial is prematurely ended in Iceland and completed in UK, Belgium,Hungary,Spain, Estonia, Italy.
- 15 Feb 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.